Saturable Binding of Finasteride to Steroid 5α-Reductase as Determinant of Nonlinear Pharmacokinetics

    Rie Suzuki, Hiroki Satoh, Hisakazu Ohtani … Yasufumi Sawada
    Studysummary This study developed a pharmacokinetic/pharmacodynamic model for finasteride, concluding that finasteride's nonlinear pharmacokinetics are likely due to its saturable binding to 5alphaR2.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on sciencedirect.com →
    Discuss this study in the Community →

    Research cited in this study 6

    1. A Model for the Turnover of Dihydrotestosterone in the Presence of the Irreversible 5α-Reductase Inhibitors GI198745 and Finasteride Clinical Pharmacology & Therapeutics · 1998
    2. PNU 157706, A Novel Dual Type I and II 5α-Reductase Inhibitor The Journal of Steroid Biochemistry and Molecular Biology · 1998
    3. Mechanism-Based Inhibition of Human Steroid 5α-Reductase by Finasteride: Enzyme-Catalyzed Formation of NADP-Dihydrofinasteride, a Potent Bisubstrate Analog Inhibitor Journal of the American Chemical Society · 1996
    4. Clinical Pharmacokinetics and Pharmacodynamics of Finasteride Clinical Pharmacokinectics · 1996
    5. 5α-Metabolism in Finasteride-Treated Subjects and Male Pseudohermaphrodites with Inherited 5α-Reductase Deficiency European Urology · 1991
    6. Species Differences in Prostatic Steroid 5α-Reductases of Rat, Dog, and Human Endocrinology · 1985

    Related research 2

    1. Saturable Binding of Finasteride to Steroid 5α-Reductase as Determinant of Nonlinear Pharmacokinetics Drug Metabolism and Pharmacokinetics · 2010
    2. Effect of Finasteride, a 5 Alpha-Reductase Inhibitor, on Serum Gonadotropins in Normal Men The Journal of Clinical Endocrinology and Metabolism · 1992